Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies
Recruiting now
Conditions studied: Migraine
In brief
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Key facts
- Study ID
- NCT06459648
- Run by
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
- People needed
- 350
- Starts
- 2023-04-26
- Expected to finish
- 2026-07-01
- Last updated by the study team
- 2026-07-02
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients aged between 18 and 65 years.
- Caucasian ethnicity.
- Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
- Have at least one year of history of migraine.
- Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
- Patients able to describe their clinical situation and the characteristics of their headache.
- Grant your informed consent.
You may not qualify if…
- Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
- Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
- Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.
Where it is running
- Hospital Clínico Universitario Lozano Blesa — Zaragoza, Aragon, Spain (enrolling)
- Hospital Universitario Donostia — Donostia / San Sebastian, Basque Country, Spain (enrolling)
- Hospital Universitario Marqués de Valdecilla — Santander, Cantabria, Spain (enrolling)
- Hospital Clínico Universitario de Valladolid — Valladolid, Castille and León, Spain (enrolling)
- Hospital Universitari Vall d'Hebron Research Institute — Barcelona, Catalonia, Spain (enrolling)
- Hospital Universitario de La Princesa — Madrid, Madrid, Spain (enrolling)
- Hospital Universitario Politécnico La Fe — Valencia, Valencia, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.